anti-Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) Antikörper

anti-Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) Antikörper (CDKN2A)
Auf finden Sie aktuell 0 Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) Antikörper von unterschiedlichen Herstellern. Insgesamt sind aktuell 0 Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) Produkte verfügbar.
ARF, ARF-INK4a, CDK4I, CDKN2, CMM2, INK4, INK4A, INK4a-ARF, Ink4a/Arf, MLM, MTS-1, MTS1, P14, P14ARF, P16, p16(INK4a), P16-INK4A, p16Cdkn2a, P16INK4, p16INK4a, P19, p19, P19ARF, Pctr1, TP16
Alle Antikörper anzeigen Gen GeneID UniProt
Anti-Ratte CDKN2A CDKN2A 25163 Q9R0Z3
Anti-Human CDKN2A CDKN2A 1029 P42771 , Q8N726
Anti-Maus CDKN2A CDKN2A 12578 P51480 , Q64364

Weitere Synonyme anzeigen

Weitere Antikörper gegen Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) Interaktionspartner

Human Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) Interaktionspartner

  1. The loss of heterozygosity methylation in the promoter region of the CDKN2A gene, occurred only in the rhabdomyosarcomatous cells with increases in both p16 and p14 (zeige S100A9 Antikörper) expression.

  2. have shown that p16(INK4A) negatively controls leptin (zeige LEP Antikörper) at the mRNA level through microRNAs 141 and 146b-5p (miR (zeige MLXIP Antikörper)-141 and miR (zeige MLXIP Antikörper)-146b-5p), which bind the leptin (zeige LEP Antikörper) mRNA at a specific sequence in the 3' untranslated region

  3. DEK (zeige DEK Antikörper) correlates with IL6 (zeige IL6 Antikörper) expression in HPV16+/p16+ oropharyngeal squamous cell carcinomas (OPSCC).

  4. P16 DNA methylation (zeige HELLS Antikörper) in in patients with B cell non-Hodgkin lymphoma

  5. Here we present, as far as we are aware, the first case of metastatic microcystic adnexal carcinoma with DNA sequencing results indicating a mutation in TP53 (zeige TP53 Antikörper) and chromosomal losses in cyclin dependent kinase inhibitor 2A (CDKN2A) and cyclin dependent kinase inhibitor 2B (CDKN2B (zeige CDKN2B Antikörper)).

  6. MEK (zeige MAP2K1 Antikörper) activation cooperates with Cdkn2a and Pten (zeige PTEN Antikörper) inactivation to induce melanoma

  7. SIX homeobox 1 (SIX1 (zeige SIX1 Antikörper)) regulates cellular senescence by a p16INK4A (p16)-dependent mechanism.

  8. EGF (zeige EGF Antikörper) induces hair follicle-derived mesenchymal stem cell proliferation through the EGFR (zeige EGFR Antikörper)/ERK (zeige EPHB2 Antikörper) and AKT (zeige AKT1 Antikörper) pathways, but not through STAT-3 (zeige STAT3 Antikörper). The G1/S transition was stimulated by upregulation of cyclinD1 and inhibition of p16 expression.

  9. results provide evidence for the influence of genetic variants at CDKN2A/B locus with the risk of developing B-AL

  10. Case Report: knee joint malignant tenosynovial giant cell tumor with CDKN2A/B genomic alteration.

Mouse (Murine) Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) Interaktionspartner

  1. Loss of p16(INK4a) expression is associated with tumorigenesis.

  2. TBK1 (zeige TBK1 Antikörper) regulates p16 expression and retinal ganglion cell senescence.

  3. median survival of KPIC mice was longer than that of LSL-KrasG12D; Ink4flox/flox; Ptf1/p48 (zeige PTF1A Antikörper)-Cre mice (KIC) (89 vs 62 days) and shorter than that of KRAS (KrasG12D), TP53 (zeige TP53 Antikörper) (Trp53R172H/+) and Ptf1/p48 (zeige PTF1A Antikörper)-Cre (KPC) mice

  4. importance of p19(Arf) for the cellular response to the low-level DNA damage incurred in culture or upon oncogene (zeige RAB1A Antikörper) expression, providing new insight into how p19(Arf) serves as a tumor suppressor.

  5. p19ARF prevents neoplastic transformation of Trp53 (zeige TP53 Antikörper)-deficient hepatocytes.

  6. Cdkn2a gene deletion is associated with colorectal carcinomas.

  7. p16 deficiency promotes nonalcoholic steatohepatitis via dysregulation of lipid metabolism and development of hepatic oxidative stress.

  8. Data show that the Wnt (zeige WNT2 Antikörper)-effector hepatocyte nuclear factor 1-alpha (Tcf1 (zeige HNF1A Antikörper)) is recruited to and triggers transcription of the Ink4/Arf tumor suppressor locus, such as as p15Ink4b (zeige CDKN2B Antikörper), p16Ink4a and p19Arf.

  9. deletion of the Cdkn2a gene in p53 (zeige TP53 Antikörper)(R172H) -induced SCCs promoted a dramatic increase in metastasis rates and a shorter survival in mice that developed these tumours, compared with those observed in mice with tumours in which Cdkn2a was deleted in the presence of a p53 (zeige TP53 Antikörper) loss-of-function mutation or wild-type p53 (zeige TP53 Antikörper).

  10. loss of Brca1 (zeige BRCA1 Antikörper), a tumor suppressor that functions in DNA damage repair, in the mammary epithelium induced senescence with induction of p16 and a decline of stem cell function, which was rescued by p16 loss.

Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) Antigen-Profil

Beschreibung des Gens

This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene\; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.

Alternative names and synonyms associated with Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A)

  • cyclin-dependent kinase inhibitor 2A (Cdkn2a) Antikörper
  • cyclin-dependent kinase inhibitor 2A (LOC100340625) Antikörper
  • cyclin-dependent kinase inhibitor 2A (CDKN2A) Antikörper
  • ARF Antikörper
  • ARF-INK4a Antikörper
  • CDK4I Antikörper
  • CDKN2 Antikörper
  • CMM2 Antikörper
  • INK4 Antikörper
  • INK4A Antikörper
  • INK4a-ARF Antikörper
  • Ink4a/Arf Antikörper
  • MLM Antikörper
  • MTS-1 Antikörper
  • MTS1 Antikörper
  • P14 Antikörper
  • P14ARF Antikörper
  • P16 Antikörper
  • p16(INK4a) Antikörper
  • P16-INK4A Antikörper
  • p16Cdkn2a Antikörper
  • P16INK4 Antikörper
  • p16INK4a Antikörper
  • P19 Antikörper
  • p19 Antikörper
  • P19ARF Antikörper
  • Pctr1 Antikörper
  • TP16 Antikörper

Bezeichner auf Proteinebene für CDKN2A

CDK4I , Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4) , cell cycle inhibitor , cell cycle regulator , cyclin-dependent kinase 4 inhibitor A , cyclin-dependent kinase inhibitor 2a p16Ink4a , cyclin-dependent kinase inhibitor 2a p19Arf , p16-INK4 , p16-INK4a , CDK4 inhibitor p16-INK4 , cell cycle negative regulator beta , cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) , multiple tumor suppressor 1 , cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4) , cyclin-dependent kinase inhibitor 2A, isoforms 1/2 , cyclin-dependent kinase inhibitor protein , mitochondrial smARF

25163 Rattus norvegicus
100731972 Cavia porcellus
100340625 Oryctolagus cuniculus
1029 Homo sapiens
12578 Mus musculus
Haben Sie etwas anderes gesucht?